Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 20 2024 - 8:00AM
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”),
a global pharmaceutical company whose mission is to be invaluable
to patients, physicians, and partners concerned with retinal
health, and maintaining better vision longer, today announced that,
pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with
the appointments of (i) Mr. Todd Wood as President of U.S.
Operations of the Company, (ii) Mr. Elliot Maltz as Chief Financial
Officer of the Company, and (iii) five non-executive employees, the
Compensation Committee of the Board of Directors of the Company
(the “Compensation Committee”) approved certain inducement grants
under the Alimera Sciences, Inc. 2024 Equity Inducement Plan to
each of Mr. Wood, Mr. Maltz, and the five other persons who were
not previously an employee or non-employee director of the Company
(collectively, the “Inducement Grants”).
The Compensation Committee approved granting on March 11, 2024,
as an inducement material to each new employee’s employment,
125,000 restricted stock units and 125,000 performance-based
restricted stock units to Mr. Wood; 75,000 restricted stock units
and 75,000 performance-based restricted stock units to Mr. Maltz;
and options to collectively purchase up to 24,500 shares of common
stock of the Company to the five other new, non-executive
employees. The stock options have an exercise price of $3.77 per
share, which is equal to the closing price of a share of the
Company’s common stock on the Nasdaq Global Market on March 11,
2024.
The restricted stock unit awards and the stock option awards
will vest over four years, with 25% of the award vesting on the
one-year anniversary of the employment commencement date and 75% of
the award vesting in equal installments over the following
thirty-six (36) months, subject to continued employment with the
Company through each applicable vesting date. One third (1/3) of
the performance-based restricted stock unit awards will vest
annually during a three-year performance period if either one of
the pre-established annual revenue target or stock price target is
satisfied during such performance year, subject to continued
employment with the Company through the vesting dates.
Each Inducement Grant was awarded as an inducement material to
the employee’s commencement of employment in accordance with Nasdaq
Listing Rule 5635(c)(4), and each such Inducement Grant Each award
is subject to the terms and conditions of the Alimera Sciences,
Inc. 2024 Equity Inducement Plan and the grant agreements
evidencing the awards.
About Alimera Sciences, Inc.
Alimera Sciences is a global pharmaceutical company whose
mission is to be invaluable to patients, physicians and partners
concerned with retinal health and maintaining better vision longer.
For more information, please visit www.alimerasciences.com.
For
investor inquiries: Scott Gordonfor Alimera
Sciencesscottg@coreir.com |
|
For
media inquiries:Jules Abrahamfor Alimera
Sciencesjulesa@coreir.com |
|
|
|
Forward Looking Statements
This press release includes “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding, among other things, Alimera’s expectations with respect
to its business strategy, future operations, projected growth, and
anticipated impact of the YUTIQ acquisition. Words such as
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,”
“plan,” “contemplates,” “predict,” “project,” “target,” “likely,”
“potential,” “continue,” “ongoing,” “will,” “would,” “should,”
“could,” or the negative of these terms and similar expressions or
words, identify forward-looking statements. Forward-looking
statements are based on current expectations and involve inherent
risks and uncertainties (some of which are beyond Alimera’s
control), including factors that could delay, divert or change any
of them, and could cause actual results to differ materially from
those projected in these forward-looking statements. These risks
and uncertainties include, but are not limited to, those factors
discussed in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections
of Alimera’s most recently filed Annual Report on Form 10-K, most
recently filed Quarterly Report on Form 10-Q, and any of Alimera’s
subsequent filings with the Securities and Exchange Commission
(SEC) and available on the SEC’s website at www.sec.gov.
All forward-looking statements contained in this press release
are expressly qualified by the cautionary statements contained or
referred to herein. Alimera cautions investors not to rely on the
forward-looking statements Alimera makes or that are made on its
behalf as predictions of future events. These forward-looking
statements speak only as of the date of this press release. Alimera
undertakes no obligation to publicly update or revise any of the
forward-looking statements made in this press release, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities laws.
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Jul 2023 to Jul 2024